US HB597 | 2021-2022 | 117th Congress

Status

Spectrum: Partisan Bill (Democrat 27-0)
Status: Introduced on January 28 2021 - 25% progression, died in committee
Action: 2021-03-22 - Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
Pending: House Subcommittee on Courts, Intellectual Property, And The Internet Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To require any COVID-19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Pandemic Treatment Access and Affordability Act of 2021

Sponsors


History

DateChamberAction
2021-03-22HouseReferred to the Subcommittee on Courts, Intellectual Property, and the Internet.
2021-02-02HouseReferred to the Subcommittee on Health.
2021-01-28HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2021-01-28HouseIntroduced in House

Subjects


US Congress State Sources


Bill Comments

feedback